XFOR - X4 Pharmaceuticals, Inc
IEX Last Trade
0.7055
0 0%
Share volume: 428,362
Last Updated: Tue 24 Dec 2024 03:30:48 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.45%
PREVIOUS CLOSE
CHG
CHG%
$0.71
-0.14
0.24%
Fundamental analysis
13%
Profitability
8%
Dept financing
8%
Liquidity
50%
Performance
10%
Performance
5 Days
-4.65%
1 Month
82.15%
3 Months
-13.43%
6 Months
-39.48%
1 Year
-15.50%
2 Year
-29.03%
Key data
Stock price
$0.71
DAY RANGE
$0.53 - $0.57
52 WEEK RANGE
$0.36 - $1.60
52 WEEK CHANGE
-$15.50
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Paula S. Ragan
Region: US
Website: x4pharma.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: x4pharma.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor. The company is also developing X4P-002, a CXCR4 antagonist for the. treatment of brain cancers.
Recent news